Major Depressive Disorder Adjunctive Therapy Investigational Medication Study
This is an 18- to 19-week study in patients with major depressive disorder who have an inadequate response to certain other antidepressants. The study will include a one- to two-week screening period, followed by an eight-week, open-label period of treatment with an antidepressant, followed by an eight-week, double-blind treatment period with the investigational medication or placebo added to the antidepressant therapy, followed by a one-week safety follow-up period. A 26-week open-label extension study may also be available to those who complete the lead-in study.
In order to participate you must meet the following criteria:
- Are 18-65 years of age.
- Have major depressive disorder, with current episode lasting between two and 12 months.
- Have failure to an adequate trial of an antidepressant during the current depressive episode.
You will be excluded from the study if any of the following criteria apply to you:
- Have certain other diagnoses.
- Have a history of ECT and/or certain other treatments during the current episode or within 6 months of study.
- Have current, or history of, substance use or dependence.
- Have certain other medical conditions.
- Have current, or history of, cataracts, eye surgery, laser treatment.
This is a partial list of eligibility requirements.